ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Result Summary for Survey: Management of N2 disease in NSCLC
Wednesday, June 9, 2010
This survey was posted during October 2006.
- There were 117 responses to this survey, with the majority of surgeons living in North America and Europe.
- Just over half of physicians use PET routinely for evaluating N2 disease.
- One third of physicians use PET only when mediastinal or hilar lymph nodes are abnormal on CT.
- The vast majority of surgeons believe that histologic confirmation is necessary when CT and PET show abnormal N2 lymph nodes.
- Most surgeons perform mediastinoscopy only when there is evidence on CT or PET for abnormal hilar or mediastinal nodes.
- The vast majority of surgeons do not operate on documented N2 disease until completion of induction therapy.
- The was a considerable range of opinions on how to manage N2 disease after induction therapy, with responses equally divided among requiring sterilization of N2 nodes, clinical response in N2 nodes, or completely resectable disease.
|
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
|
|||||||||||||||||||||||||||||||||||
![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
|